Regeneron Pharmaceuticals and Sanofi have shut down the late-stage clinical trials that were testing whether their existing arthritis drug, Kevzara, could improve the condition of COVID-19 patients who were on ventilators.
The bottom line: Kevzara fared no better than a placebo, as it failed to help COVID-19 patients recover or prevent death. Remdesivir remains as the only treatment that has shown any kind of benefit for sick coronavirus patients, although dexamethasone appears to hold the most promise.